Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_2
2
50%
Ph phase_3
1
25%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Other(4)

Detailed Status

unknown4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)

Trials by Status

unknown4100%

Recent Activity

0 active trials
Showing 4 of 4
unknownphase_2

A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer

NCT04398940
unknownphase_2

Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

NCT04056572
unknownphase_3

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

NCT04009317
unknownphase_1

A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics

NCT03099330

Clinical Trials (4)

Showing 4 of 4 trials
NCT04398940Phase 2

A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer

Unknown
NCT04056572Phase 2

Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Unknown
NCT04009317Phase 3

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

Unknown
NCT03099330Phase 1

A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4